Data Presented at Annual Scientific Sessions of American Heart Association
COLUMBIA, Md., Nov. 22 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (NASDAQ: MATK) today announced the results of a clinical investigation examining the effects of docosahexaenoic acid (DHA) on endothelial function in children with elevated blood lipid levels (hyperlipidemia). Hyperlipidemia in children is a risk factor for early coronary heart disease. Clinical data demonstrated that when patients supplemented a specialized diet with DHA, they showed improved endothelial function as compared to the specialized diet alone. Complete study findings were presented on November 18 at the 2002 Scientific Sessions of the American Heart Association.
The double-blind, placebo-controlled, randomized crossover trial, which enrolled over 14 overweight subjects between the ages of 10 and 19, measured improved endothelial function by changes in the patients' endothelium- dependent flow mediated dilation (FMD). Researchers found that, when patients received DHA, they experienced significant improvements in their arterial flow, indicating that their arteries had become more flexible.
"The exciting news here is that supplementation with DHA increased blood vessel dilation, an important indicator of cardiovascular health," said lead investigator Marguerite Engler, Ph.D., RN, MS, FAHA, University of California, San Francisco. "By adding DHA to their specialized diets, we were able to improve the children's cardiovascular health."
"It's great to see clinical studies that are now pinpointing the cardiovascular benefits of DHA," stated Henry Linsert, Jr., Martek Chairman and CEO.
The DHA used in this study was Martek's vegetarian, contaminant-free form of the omega-3 fatty acid. Early this week, the American Heart Association published a scientific statement outlining the findings of a comprehensive report that examined the cardiovascular health benefit of omega-3 fatty acids such as DHA. The report concluded that healthy people should eat omega-3 fatty acids from fish and plant sources to protect their hearts.
Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
This press release contains forward-looking statements regarding Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.
CONTACT: Angela Tsetsis, Director of Marketing, of Martek Biosciences Corporation, +1-410-740-008.